RxDoctor Payments Data

Leif Christianson

Interventional Cardiology · Duluth, MNNPI 1477715530

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Boston Scientific at 58.1% of the total. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.

$4,916in general payments, 2019–2025

Across 148 payments — averaging $33.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Edwards Lifesciences$1K
  • Shockwave Medical, Inc$312
  • Teleflex LLC$141
  • Abiomed$94
  • Medtronic$93
  • plus $206 from 5 others

What the payments were for

  • Travel & lodging$2,23245%
  • Food & beverage$2,68355%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,916 in reported general payments places this provider in the 45th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$101,960
Medicare patients
971
Services billed
1,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$96,313
Repatha SureclickEvolocumab32$22,787
JardianceEmpagliflozin17$19,864
EntrestoSacubitril/Valsartan12$15,154
Metoprolol Succinate180$4,167
Ranolazine ErRanolazine21$3,317
ClopidogrelClopidogrel Bisulfate180$2,794
Atorvastatin Calcium142$2,194
Rosuvastatin Calcium151$2,110
Isosorbide Mononitrate ErIsosorbide Mononitrate84$1,364
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$1,291
Lisinopril110$973
Carvedilol94$873
Losartan Potassium69$872
Metoprolol Tartrate58$620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$33$15,15412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 84 interventional cardiology providers in Minnesota.

Other interventional cardiology in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →